SNPs and taxane toxicity in breast cancer patients-Reference-Cited by-同舟云学术

SNPs and taxane toxicity in breast cancer patients

Published:2014-11 Issue:15 Volume:15 Page:1845-1858
ISSN:1462-2416
Container-title:Pharmacogenomics
language:en
Short-container-title:Pharmacogenomics

Author:

Bosó Virginia¹²³,Herrero María José¹²,Santaballa Ana⁴,Palomar Laura⁴,Megias Juan E¹²³,de la Cueva Helena⁴,Rojas Luis⁵,Marqués María Remedios¹³,Poveda José Luis¹³,Montalar Joaquin⁴,Aliño Salvador F¹⁶⁷

Affiliation:

1. Pharmacogenetics Unit, Pharmacy Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain

2. La Fe Institute for Health Research, IIS La Fe, Valencia, Spain

3. Pharmacy Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain

4. Oncology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain

5. Department of Internal Medicine, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile

6. Clinical Pharmacology Unit, Hospital Universitari i Politècnic La Fe, Valencia, Spain

7. Department of Pharmacology, Faculty of Medicine, Universidad de Valencia, Spain

Abstract

Aim: In order to identify genetic variants associated with taxanes toxicity, a panel with 47 SNPs in 20 genes involved in taxane pathways was designed. Patients & methods: Genomic DNA of 113 breast cancer patients was analyzed (70 taking docetaxel, 43 taking paclitaxel). Results: Two SNPs associated with docetaxel toxicity were identified: CYP3A4*1B with infusion-related reactions; and ERCC1 Gln504Lys with mucositis (p ≤ 0.01). Regarding paclitaxel toxicity: CYP2C8 HapC and CYP2C8 rs1934951 were associated with anemia; and ERCC1 Gln504Lys with neuropathy (p ≤ 0.01). Conclusion: Genes involved in DNA repair mechanisms and reactive oxygen species levels influence taxane toxicity in cancer patients treated with chemotherapy schemes not containing platinum. These findings could lead to better treatment selection for breast cancer patients.

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/pgs.14.127

Reference50 articles.

1. International Agency for Research on Cancer (IARC). www.iarc.fr.

2. Pharmacogenetics of breast cancer therapies

3. Pharmacogenetics in Breast Cancer Therapy

4. Pharmacogenetics in breast cancer: focus on hormone therapy, taxanes, trastuzumab and bevacizumab

5. Overview of personalized medicine in the disease genomic era

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacogenomic predictor of long-term residual chemotherapy-induced peripheral neuropathy in ovarian cancer survivors: A substudy of the GINECO Vivrovaire study;Gynecologic Oncology;2024-08

2. Breast Cancer: Clinical–Epidemiological Profile and Toxicities of Women Receiving Treatment with Taxanes in the Amazon Region;Journal of Personalized Medicine;2023-09-30

3. CYP3A genetic variation and taxane-induced peripheral neuropathy: a systematic review, meta-analysis, and candidate gene study;Frontiers in Pharmacology;2023-07-04

4. Perspective Chapter: Appraisal of Paclitaxel (Taxol) Pros and Cons in the Management of Cancer – Prospects in Drug Repurposing;Drug Repurposing - Advances, Scopes and Opportunities in Drug Discovery;2023-06-07

5. Breast cancer pharmacogenetics: a systematic review;Pharmacogenomics;2023-01